



**CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with Immunotherapy CDR404 for Treatment of Solid Tumors at SITC 2023**

*Therapeutic potential of CDR404, as a first-of-its-kind precision immunotherapy for HLA-A\*02:01+ patients with MAGE-A4+ squamous non-small cell lung carcinoma (SQ-NSCLC)*

*Development of a Quantitative Systems Pharmacology (QSP) model to facilitate discovery of safe and efficacious doses for upcoming Phase 1 trial*

Zürich, Switzerland, November 3, 2023 – [CDR-Life Inc.](#), in the run-up to initiation of its first Phase 1 clinical trial, presented two posters for CDR404, a first-of-its-kind, antibody-based, bivalent & bispecific MAGE-A4 T-cell engager (TCE) targeting MAGE-A4, an intracellular cancer protein with expression in several frequent and difficult to treat solid tumors, at the Society for Immunotherapy of Cancer’s (SITC) 38<sup>th</sup> Annual Meeting.

“The absence of actionable genetic alterations makes SQ-NSCLC a difficult-to-treat cancer after relapse from immune checkpoint blockade. The demonstration of high MAGE-A4 protein expression in SQ-NSCLC and potent preclinical cytotoxicity of CDR404, highlights the therapeutic promise of CDR404 in HLA-A\*02:01+ patients with SQ-NSCLC. Results from the second presentation show that leveraging the QSP model for the prediction of CDR404 doses that are likely to be safe and efficacious will enable CDR-Life to select the most effective dose to carry forward into a future registrational study,” said Swethajit Biswas, M.D., Ph.D., Chief Medical Officer at CDR-Life.

“These milestones underscore the continued advancement of CDR404’s potential as an off-the-shelf precision immunotherapy for MAGE-A4+ solid tumors. The unique Fab-(scFv)<sub>2</sub> molecular format and CD3 binding properties of CDR404 is very different compared to previous T-cell engagers which have targeted MAGE-A4+ tumors, thereby optimizing the probability-of-success in the clinic,” Dr. Biswas concluded.

Poster presentation highlights include:

**Abstract 1397**

- SQ-NSCLC had the highest MAGE-A4 mRNA expression levels among solid cancers in the TCGA database.
- Immunohistochemistry showed positive MAGE-A4 staining in 28/50 SQ-NSCLC samples.
- Treatment with four different doses of CDR404 induced complete tumor regression in the in vivo SQ-NSCLC NCI-H1703 xenograft model.

**Abstract 195**

- The QSP model builds a preliminary understanding of the relationship between MAGE-A4 expression and intra-tumor T-cell density in determining CDR404 anti-tumor activity.

- The QSP model predicted doses of CDR404 which might have the most favorable benefit-risk profile for patients in the Phase 1 trial.

Poster Presentation Details:

Title: CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)

Abstract Number: 1397

Presentation Date: Friday, November 3, 2023

Presentation Time: 12:00 p.m. - 1:30 p.m. PDT

Title: Overcoming the dose-response prediction limitation from bench to clinic for T-cell engagers: Using Quantitative Systems Pharmacology (QSP) modeling in the development of CDR404 for solid tumors

Abstract Number: 195

Presentation Date: Friday, November 3, 2023

Presentation Time: 12:00 p.m. - 1:30 p.m. PDT

**About CDR-Life**

CDR-Life is developing highly specific antibody therapeutics to target intracellular proteins presented on the major histocompatibility complex (MHC). Our versatile MHC-targeted antibody platform increases access to a vast array of antigens that were not previously addressable, to develop a pipeline of first in class therapeutics across a broad range of solid tumors. With a team of proven drug development experts and backed by leading cross-Atlantic investors, we are working to redirect and activate the patient's own immune system to eliminate their tumors.

**Contacts**

Media:

Holly Hancock

MacDougall Advisors

hhancock@macdougall.bio